Soleus Capital Management, L.P. Alnylam Pharmaceuticals, Inc. Transaction History
Soleus Capital Management, L.P.
- $1.18 Billion
- Q3 2024
A detailed history of Soleus Capital Management, L.P. transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Soleus Capital Management, L.P. holds 59,400 shares of ALNY stock, worth $14.6 Million. This represents 1.39% of its overall portfolio holdings.
Number of Shares
59,400
Previous 71,700
17.15%
Holding current value
$14.6 Million
Previous $17.4 Million
6.22%
% of portfolio
1.39%
Previous 1.77%
Shares
5 transactions
Others Institutions Holding ALNY
# of Institutions
644Shares Held
109MCall Options Held
1.28MPut Options Held
1.21M-
Capital World Investors Los Angeles, CA16.5MShares$4.07 Billion0.73% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.6MShares$3.12 Billion0.06% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$2.35 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA5.24MShares$1.29 Billion0.31% of portfolio
-
Wellington Management Group LLP Boston, MA4.95MShares$1.22 Billion0.24% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $30.3B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...